Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EBITDA: 2013-2025

Historic EBITDA for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to -$68.7 million.

  • Ocular Therapeutix's EBITDA fell 49.35% to -$68.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.8 million, marking a year-over-year decrease of 77.57%. This contributed to the annual value of -$171.8 million for FY2024, which is 108.52% down from last year.
  • Latest data reveals that Ocular Therapeutix reported EBITDA of -$68.7 million as of Q3 2025, which was down 1.56% from -$67.6 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's EBITDA ranged from a high of -$17.8 million in Q1 2022 and a low of -$68.7 million during Q3 2025.
  • In the last 3 years, Ocular Therapeutix's EBITDA had a median value of -$43.6 million in 2024 and averaged -$41.3 million.
  • Per our database at Business Quant, Ocular Therapeutix's EBITDA grew by 11.84% in 2022 and then slumped by 152.25% in 2024.
  • Over the past 5 years, Ocular Therapeutix's EBITDA (Quarterly) stood at -$18.0 million in 2021, then fell by 7.27% to -$19.4 million in 2022, then dropped by 3.56% to -$20.1 million in 2023, then slumped by 152.25% to -$50.6 million in 2024, then crashed by 49.35% to -$68.7 million in 2025.
  • Its EBITDA was -$68.7 million in Q3 2025, compared to -$67.6 million in Q2 2025 and -$63.9 million in Q1 2025.